ADAR1 Capital Management »

Immunovant shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Immunovant (IMVT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Immunovant

Tip: Access up to 7 years of quarterly data

All positions including Immunovant held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunovant by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $5.7M 134k 42.13

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Immunovant

Vanguard Group
Point72 Asset Management
Perceptive Advisors
T. Rowe Price Associates
Alpine Partners VI
Logos Global Management
Cormorant Asset Management
Citadel Advisors
Commodore Capital
Boxer Capital
Redmile Group
Fred Alger Management
Millennium Management
Susquehanna International
Ikarian Capital

View all funds holding Immunovant